Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris

University Hospital, Ghent26 enrolled

Overview

Patients with vitiligo vulgaris are treated with Pimecrolimus twice a day during 6 months. After a baseline visit, patient returns for a control visit after 3 and 6 months of treatment. One reference lesion is clinically evaluated with pictures.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Vitiligo Vulgaris

Interventions

Application of pimecrolimusDRUG

Eligibility

Sex: ALLMin age: 6 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Active or stable vitiligo vulgaris * lesions at head or neck + maximum 10% lesions at the rest of the body Exclusion Criteria: * Topica during last 2 weeks * Photo(chemo)therapy during last 4 weeks * Segmentary vitiligo

Locations (1)

University Hospital Ghent

Ghent, Belgium

Outcomes

Primary Outcomes

Repigmentation percentage of the reference lesion after 6 months.

Secondary Outcomes

Number of patients with repigmentation after 3 and 6 months.

Repigmentation percentage of the reference lesion after 3 months.

Adverse events (month 3 and 6).

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.